Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p

[1]  Jacqueline A. Hall,et al.  CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.

[2]  K. Dewar,et al.  Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1‐q25.2 , 2005, Molecular carcinogenesis.

[3]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  U. Thorsteinsdóttir,et al.  Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues , 2004, Genes, chromosomes & cancer.

[5]  T. Hudson,et al.  Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.

[6]  A. Stewart,et al.  Vgl-4, a Novel Member of the Vestigial-like Family of Transcription Cofactors, Regulates α1-Adrenergic Activation of Gene Expression in Cardiac Myocytes* , 2004, Journal of Biological Chemistry.

[7]  G. Hendy,et al.  Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. , 2004, Molecular endocrinology.

[8]  A. Reith,et al.  Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. , 2003, Neoplasia.

[9]  E. Fisher,et al.  Microcell-mediated chromosome transfer (MMCT): small cells with huge potential , 2003, Mammalian Genome.

[10]  Martin Fussenegger,et al.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.

[11]  G. Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Science.

[12]  T. Hudson,et al.  Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines , 2003, Oncogene.

[13]  B. Davidson,et al.  Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: A possible activation pathway? , 2003, Cancer and Metastasis Reviews.

[14]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[15]  A. Stewart,et al.  Mammalian Vestigial-like 2, a Cofactor of TEF-1 and MEF2 Transcription Factors That Promotes Skeletal Muscle Differentiation* , 2002, The Journal of Biological Chemistry.

[16]  J. Minna,et al.  Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers , 2002, Oncogene.

[17]  J. Adams,et al.  A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. , 2002, Current opinion in chemical biology.

[18]  M. Shibuya,et al.  Expression of Vascular Endothelial Growth Factor and E‐Cadherin in Human Ovarian Cancer: Association with Ascites Fluid Accumulation and Peritoneal Dissemination in Mouse Ascites Model , 2002, Japanese journal of cancer research : Gann.

[19]  J. Minna,et al.  Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers , 2002, Oncogene.

[20]  K. Huebner.  Tumor suppressors on 3p: A neoclassic quartet , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Rabbitts,et al.  Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Berkowitz,et al.  SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.

[23]  D. Gisselsson,et al.  Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution , 2001, Genes, chromosomes & cancer.

[24]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[25]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[26]  Elizabeth R. Smith,et al.  Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells , 2000, Oncogene.

[27]  A. Schäffer,et al.  Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis , 2000, Genes, chromosomes & cancer.

[28]  D. Bostwick,et al.  Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma , 2000, Genes, chromosomes & cancer.

[29]  M Aickin,et al.  Chromosome abnormalities in ovarian adenocarcinoma: I. nonrandom chromosome abnormalities from 244 cases , 1999, Genes, chromosomes & cancer.

[30]  D. Alberts,et al.  Chromosome abnormalities in ovarian adenocarcinoma: II. prognostic impact of nonrandom chromosome abnormalities in 244 cases , 1999, Genes, chromosomes & cancer.

[31]  J. Mesirov,et al.  Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Mes-Masson,et al.  Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites , 1999, Molecular carcinogenesis.

[33]  C. Cooper,et al.  Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. , 1999, Journal of the National Cancer Institute.

[34]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[35]  A. Mes-Masson,et al.  Mapping of chromosome 3p deletions in human epithelial ovarian tumors , 1998, Oncogene.

[36]  A. Baldini,et al.  DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.

[37]  C. Bucana,et al.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. , 1998, Journal of the National Cancer Institute.

[38]  L. Twiggs,et al.  Vascular endothelial growth factor expression in early stage ovarian carcinoma , 1997, Cancer.

[39]  M. Chevrette,et al.  Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids , 1996, Molecular and cellular biology.

[40]  L. Hedrick,et al.  Chromosome abnormalities in primary endometrioid ovarian carcinoma. , 1996, Cancer genetics and cytogenetics.

[41]  A. Mes-Masson,et al.  Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. , 1994, Experimental cell research.

[42]  Y. Sanchez,et al.  A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Farrall,et al.  Gene targeting for somatic cell manipulation: rapid analysis of reduced chromosome hybrids by Alu-PCR fingerprinting and chromosome painting. , 1992, Human molecular genetics.

[44]  F. Mitelman,et al.  Chromosome aberrations in 35 primary ovarian carcinomas , 1992, Genes, chromosomes & cancer.

[45]  Larry W. Swanson,et al.  Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1 , 1990, Nature.

[46]  P. Avner,et al.  Characterization of a human ovarian teratocarcinoma‐derived cell line , 1980, International journal of cancer.

[47]  Vincent J. Carey,et al.  Visualization and Annotation of Genomic Experiments , 2003 .

[48]  A. Mes-Masson,et al.  Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer , 2002, Molecular carcinogenesis.

[49]  T. Hudson,et al.  Characterization of variability in large-scale gene expression data: implications for study design. , 2002, Genomics.

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[51]  M. Chevrette,et al.  Construction and analysis of microcell hybrids containing dual selectable tagged human chromosomes. , 1995, Cytogenetics and Cell Genetics.

[52]  J. Whang‐Peng,et al.  Cytogenetic studies in ovarian cancer. , 1984, Cancer genetics and cytogenetics.